Summary Cancer risks were studied in 834 thyroid cancer patients given 'l'I (4,551 MBq, average) Iodine-131 was first described in medical practice more than 40 years ago and is still frequently used in the diagnosis and treatment of thyroid disorders (Hamilton & Lawrence, 1942; Hertz & Roberts, 1942) .
(SIR = 1.80; 95% CI1.20-2.58). No specific cancer or group of cancers could be convincingly linked to high-dose '"'I exposures since SIR did not increase after 10 years of observation. However, upper confidence intervals could not exclude levels of risk that would be predicted based on data from the study of atomic bomb survivors. We conclude that the current practice of extrapolating the effects of high-dose exposures to lower-dose situations is unlikely to seriously underestimate radiation hazards for low LET radiation.
Iodine-131 was first described in medical practice more than 40 years ago and is still frequently used in the diagnosis and treatment of thyroid disorders (Hamilton & Lawrence, 1942; Hertz & Roberts, 1942) .
In cases of nuclear explosions or reactor accidents large amounts of 131I could be spread over vast areas causing a potential hazard to human beings (Becker, 1987) . Data on risks associated with radioactive iodines are still relatively scarce despite studies of populations exposed to fallout from nuclear weapons testing (Conard, 1984; Hamilton et al., 1987) and patients receiving diagnostic (Holm et al., 1989) and therapeutic doses of '"'I (Brincker et al., 1973; Edmonds & Smith, 1986; Hoffman, 1984; Holm, 1984; Saenger et al., 1968 ).
Studies of thyroid cancer patients treated with '3'I are also rare, probably because of the low incidence of the disease and the associated small number of patients admitted to each centre. High-dose '"'I has been linked to leukaemia following treatment for thyroid cancer (Brincker et al., 1973; Edmonds & Smith, 1986 ) and also to cancers of the bladder (Edmonds & Smith, 1986) . Record-linkage studies of patients with thyroid cancer have reported increased risks of leukaemia (Teppo et al., 1985) , cancer of the breast, kidney and connective tissue (Tucker et al., 1985) , and cancer of the nervous tissue and non-Hodgkin's lymphoma (0sterlind et al., 1985) .
The present study was designed to evaluate the risk of second primary cancer in a cohort of thyroid cancer patients treated with 13'I, and to contrast the risk with that of nonexposed thyroid cancer patients.
Subjects and methods
Patient data were obtained from the oncologic centres of six university hospitals in Sweden: (1) Lund; (2) Malm6; (3) Gothenburg; (4) Stockholm; (5) Uppsala, and (6) UmeA Radiation doses to various organs were estimated assuming a thyroid uptake of 25% and using the mean value of 4,551 MBq, ICRP tables (ICRP, 1988) and the data from Smith and Edmonds (1983) . The bladder and stomach received on average 2.1 Gy, and the salivary glands and small intestine 1.9 and 1.3 Gy, respectively. The pancreas, liver, colon, lung, breast, ovary, uterus, testes, kidney, adrenal gland, and bone marrow received 0.1-0.6Gy.
All patients who originally had been diagnosed as having a thyroid cancer were included in the study. (Mattsson & Wallgren, 1984) . Patients were matched using their unique 10-digit identification number, which is given to each Swedish resident.
All patients were considered to be at risk from 2 years after the time of initial 1311 treatment (Group I), thyroid cancer diagnosis (Group II), or from 1958 if treated or diagnosed prior to that year, and until death or December (Shimizu et al., 1990) were elevated risks for solid tumours were reported after 10 years of observation. The short follow-up could be one explanation. Other reasons could be the relatively small number of patients studied and the relatively low doses to most organs. For example, a RR of 1.51 (95% CI 0.20-11.21) was estimated for leukaemia and based on the ratio of SIRs among exposed to non-exposed patients. Assuming an average dose to the bone marrow of 0.3 Gy and applying the most recent estimate of risk from the study of atomic bomb survivors of a 5.2% increase in the RR of leukaemia per 0.01 Gy (Shimizu et al., 1990) , the expected radiogenic risk in our series would be RR = 2.6. Although the possibility for this level of risk cannot be excluded since it is within the 95% CI of the observed risk, it does suggest that current estimates of radiogenic-induced leukaemia based on high-dose data are unlikely to underestimate risks at low-dose levels. For solid tumours the RR was 1.21 and the predicted value 1.2 based on the atomic bomb data estimates of a 0.41% increase per 0.01 Gy (Shimizu et al., 1990) and assuming that the average wholebody dose for patients treated with '"'I in our study was 0.5 Gy (ICRP, 1988) .
Other studies of thyroid cancer patients have reported significant risks of leukaemia (Brincker et al., 1973; & Smith, 1986) . Patients treated with lower doses of '31I for hyperthyroidism (200-900 MBq) have not been found to be at increased risk for leukaemia (Hoffman, 1984; Holm, 1984) . One survey suggests that patients with thyroid disorders might have a predisposition for developing leukaemia (Saenger et al., 1968) . Women with thyroid cancer had a higher risk than men of developing a second primary cancer. There was no marked difference between the sexes in the treatment of the thyroid cancer, age distribution, patients treated for distant metastases or cases diagnosed at autopsy. The latest findings from the A-bomb survivors did not indicate a difference between the sexes in cancer mortality, except for leukaemia where men had a higher risk (Shimizu et al., 1990) .
A statistically significant excess was observed for the salivary glands. This finding was based on three cases, one of whom also received external irradiation to the neck region. Salivary gland cancer has not previously been observed after 13'I therapy, but has been reported following relatively highdose external irradiation (Maxon et al., 1981) .
An increased risk for tumours of the adrenal gland was noted in both treatment groups, and suggests the possibility of an underlying predisposition or common etiological factors. In 1961, Sipple noted the coexistence of medullary thyroid carcinoma, pheocromocytoma and later parathyroid adenoma. Seven of the 12 endocrine tumours in this study were pheocromocytomas and three parathyroid tumours. Five patients with pheocromocytoma had a previous history of medullary thyroid carcinoma. The knowledge among physicians to search for other endocrine tumours in thyroid cancer patients could contribute to our findings.
The risk was significantly elevated for a subsequent kidney cancer (SIR = 3.00; n = 7) but not for bladder cancer (SIR = 1.61; n = 4) in Group I. This is noteworthy since the dose to the bladder was calculated to be eight times higher than for the kidney. One explanation could be the screening for pheocromocytoma. Significantly elevated risks for bladder cancer (Edmonds & Smith, 1986) and kidney cancer (Tucker et al., 1985) have previously been described.
The absence of a breast cancer excess in the "'lI treated group is noteworthy since previous studies have suggested a link with "'lI therapy (Goldman et al., 1988; Teppo et al., 1985) , or a common etiology for breast and thyroid cancer (Ron et al., 1984) . A significant excess of breast cancer was found among patients not given "'lI who survived > 10 years.
The elevated risk among patients receiving higher activity of 13I1 suggests a dose-response relationship but could be somewhat misleading since radiation doses are dependent of the thyroid 24-h uptake. Further calculations on individual organ-and whole-body doses are needed.
The close medical surveillance of cancer patients may have contributed to the detection of some cancers that would not otherwise have led to the clinically apparent disease, resulting in artefactually increased risks in both groups. No difference in the proportion of second primary cancers found at autopsy was observed in the two groups, although the autopsy rate was higher in the 'llI treated group.
External radiotherapy did not seem to have a major impact on cancer risks since the overall risk was higher in patients not receiving external radiotherapy (SIR= 1.29; 95% CI 1.07-1.54) than in patients receiving this treatment (SIR = 1.23; 95% CI 1.00-1.49). There was no difference in the percentage of patients in Groups I and II having received external radiotherapy, although the "'lI treated group were irradiated outside the neck region more often, 16% vs 6%.
The observed second primary cancers were all found in thyroid cancer patients treated at university hospitals in major cities and expected values were calculated from the Swedish population as a whole, which thus would result in an overestimate of the SIRs.
When interpreting our results several methodologic strengths and weaknesses should be considered. The strengths include the detailed information on administered "3'I activity which facilitates organ dose estimation, the availability of a nonexposed comparison group, and the accurate and complete ascertainment of subsequent malignancies through linkage with the national cancer register. Weaknesses include the relatively small number of patients studied, the possibility that selection biases might exist with regard to treatment, the roles that increased surveillance or misdiagnosed metastases might play, the use of average organ doses and not individual estimates.
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